Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 2/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23331023 | 0.95 | HSD17B10 (0.40) | CNR2HSD17B10L3MBTL1P2RX3MEN1 | |
| SCHEMBL23330863 | 0.81 | P2RX3 (0.35) | CNR2HSD17B10L3MBTL1P2RX3ALDH1A1 | |
| SCHEMBL31093317 | 0.77 | AKR1C3 (0.43) | CNR2HTR6HRH3ALDH1A1F10 | |
| SCHEMBL23331022 | 0.77 | HSD17B10 (0.38) | CNR2HSD17B10L3MBTL1P2RX3HTR6 | |
| SCHEMBL17269955 | 0.74 | POLB (0.40) | CNR2HSD17B10L3MBTL1POLBMEN1 | |
| SCHEMBL16097729 | 0.73 | CNR2 (0.42) | CNR2HSD17B10L3MBTL1HTR6ALDH1A1 | |
| SCHEMBL24393197 | 0.73 | ALDH1A1 (0.41) | CNR2HSD17B10L3MBTL1POLBMEN1 | |
| SCHEMBL30961479 | 0.72 | L3MBTL1 (0.47) | L3MBTL1KMT2AHRH3ALDH1A1F10 | |
| SCHEMBL27140547 | 0.72 | L3MBTL1 (0.47) | L3MBTL1KMT2AHRH3ALDH1A1F10 | |
| SCHEMBL31093334 | 0.71 | ALDH1A1 (0.46) | CNR2L3MBTL1MEN1KMT2AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028221-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| WO-2021083380-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海科技大学 | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028221-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP4F11, CYP4A11, HSD11B1 | CNR2 3520/4885HSD17B10 332/4885L3MBTL1 4478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.